Get a glimpse into our company and investor data—powered by the PitchBook Platform
GrantLATEST DEAL TYPE
$60KLATEST DEAL AMOUNT
Innovator of therapeutic agents against cancer. The company's platform performs the chemical synthesis and pharmaceutical testing of non-natural nucleosides as novel anti-cancer agents against hematological cancers and solid tumors.